ACR 2021

Pulmonary involvement and possible therapy concepts in…

Dear Doctor: JAKi risk factors and safety profile - is…

ARIAA: prevention study or very early treatment of RA?

No need for methotrexate in ustekinumab treatment in…

axPsA is axSpA is not...!?

IL-17 pathway important for pain in PsA

Discordance between patients and physicians in RA

Cycling JAKi compared to switching to biologic DMARD in…

Nausea & alopecia with MTX in RA

Abatacept may reduce subclinical inflammation in RA-at…

Statins reduce cardiovascular risk and​ mortality -…

Cardiovascular disease in RA

We need predictors of response for RA treatment

Long awaited - MACE data from ORAL surveillance

Tofacitinib is associated with a slightly increased…

Abatacept reduce la inflamación subclínica en pacientes…

Skifte mellom JAK hemmere sammenliknet med skifte til…

Désaccords patient/Médecin : se comprendre pour plus…

Quels effets indésirables peuvent être associés à la…

Tofacitinid se asocia con un ligero incremento del…

Lange erwartet - MACE-Daten zur ORAL Surveillance

Quels marqueurs de réponse aux traitements dans la…

Prediction of psoriatic arthritis in patients with…

Osteoporosis in PsA

Secukinumab vs TNF-α blockers in enthesitis

Pain differs: Superior effect of IL-17-inhibition vs.…

Upadacitinib in PsA

Tildrakizumab in PsA

No need for MTX in ustekinumab-treated patients

Guselkumab in axial symptoms

PET/CT in diagnosis for PsA

Joint effusions and enthesitis after physical exertion

Axial PsA MRI data

Anemia is an issue in PsA - proper treatment possible!

Guselkumab: the better ustekinumab?!

Association of C-reactive protein and non-steroidal…

Associazione di livelli di PCR e uso di FANS con gli…

Guselkumab bei axialer Symptomatik

Studio di confronto tra i vari indici compositi per la…

Anämie bei PsA ist ein Thema - effektive Therapie…

Kein Hinweis auf Vorteil einer MTX-Kombi zu Ustekinumab

Datos de RM en APs axial

Guselkumab: das bessere Ustekinumab?!

Schmerz ist nicht gleich Schmerz: Unterschied von…

Tildrakizumab bei PsA

Gelenkergüsse und Enthesitis nach körperlicher…

Upadacitinib bei PsA

PET-CT zur Quantifizierung der Entzündung

Previsione di sviluppo di artrite psoriasica in…

Secukinumab vs TNF-α Blocker bei Enthesitis

Axial PsA MRI data

Dose tapering of TNF inhibitors in axSpA

JAK inhibitors - new kids on the block

Optimización de iTNF en EspAax

Inhibidores JAK: nuevas dianas en EspAax

l’auto-monitoraggio di malattia è fattibile nella…

JAKi baricitinib successfully mastered phase II study

Kombination Belimumab und Rituximab noch kein neuer…

Secukinumab in giant cell arteritis

PET as a predictor of vascular damage in large-vessel…

A new therapeutic approach for giant cell arteritis?

Il ruolo della PET nel predire il danno vascolare nelle…

Baricitinib nell'arterite a cellule giganti recidivante

Neuer Therapieansatz für die Riesenzellarteriitis?

Vaccination against Delta variant worse in patients…

Breakthrough infections after SARS-CoV2-vaccination -…

Analysis of COVID-19 infection among vaccinated…

TNF blockers reduce the antibody response to RNA…

Should we use ultra-low-dose rituximab during the…

Anticytokine antibodies causing severe microbacterial…

Breakthrough infections after SARS-CoV2-vaccination -…

Impact of COVID-19 on patients with rheumatic diseases

Immune responses to COVID-19 vaccines

Immunresponser til COVID-19 vaksiner

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

TNF-Blocker reduzieren Antikörperantwort bei…

Womit boostern bei fehlender Serokonversion?

Durchbruchsinfektionen nach SARS-CoV2-Impfung -…

PROs from a real-world study on etanercept biosimilar -…

Skin findings in patients of color with rheumatic…

New exciting data - dietary supplements with vitamin D…

CBD - an alternative therapy for chronic pain

Therapeutic drug monitoring - a randomized controlled…

Neue spannende Daten - Nahrungsergänzung mit Vitamin D…